Thanos is considered by many to be Marvel's greatest villain and he's proved that by killing some of Marvel's most powerful ...

New bifacial rooftop solar module arrives in Australia with N-type back-contact, dual-glass and a a 30-year linear ...

Appotronics (688007.SH), the inventor of ALPD® laser display technology, delivered the pivotal visual technology that defined ...

Flywire stock has drawn renewed attention after consensus analyst price targets edged higher, rising from $15.95 to $16.59 in the latest update. This modest upward revision reflects cautious optimism ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns.

When you click on “Accept all”, you consent to ads on this site being customized to a personal profile we or our advertising ...